ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.
 PMID: 22237471       2012       Infection
Abstract: At DRV failure, the major increase was still observed for V32I; I54L, V11I, T74P and I50V also increased.


  Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
 PMID: 21545648       2012       Fundamental & clinical pharmacology
Abstract: Darunavir GIQ is defined as the ratio between darunavir trough plasma concentration and the count of darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V) corrected or not corrected by the count of mutations with positive impact (V82A and E35D).


  Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
 PMID: 19147519       2009       The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Among the eight mutations with a negative impact on the virological response, I47V, I54M, T74P and I84V were previously described as darunavir resistance-associated mutations.
Abstract: Cochran-Armitage procedure identified eight mutations with a negative impact on the virological response, namely K14R, K20I, E34Q, I47V, I54M, K55R, T74P and I84V; and two mutations (E35D and V82A) with a positive impact.


  Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India.
 PMID: 18240959       2008       AIDS research and human retroviruses
1Abstract: In the protease region it showed a major drug resistance mutation at M46I as well as ""minor"" positions F53L and T74P."


  Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
 PMID: 17425479       2007       Expert opinion on pharmacotherapy
Abstract: The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V.


  Tipranavir: a ritonavir-boosted protease inhibitor.
 PMID: 16060700       2005       Drugs
Abstract: Analysis of clinical isolates from treatment-experienced patients identified the following tipranavir resistance-associated HIV protease mutations: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V.



Browser Board

 Co-occurred Entities




   Filtrator